AR124036A1 - Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición - Google Patents

Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición

Info

Publication number
AR124036A1
AR124036A1 ARP210103113A ARP210103113A AR124036A1 AR 124036 A1 AR124036 A1 AR 124036A1 AR P210103113 A ARP210103113 A AR P210103113A AR P210103113 A ARP210103113 A AR P210103113A AR 124036 A1 AR124036 A1 AR 124036A1
Authority
AR
Argentina
Prior art keywords
formula
pharmaceutically acceptable
salt
composition
pharmaceutical composition
Prior art date
Application number
ARP210103113A
Other languages
English (en)
Spanish (es)
Inventor
Waters Susanna Holm
Joakim Mihkel Tedroff
Per Svenningsson
Original Assignee
Integrative Res Laboratories Sweden Ab
Irl 790 Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab, Irl 790 Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of AR124036A1 publication Critical patent/AR124036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP210103113A 2020-11-10 2021-11-09 Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición AR124036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20206645 2020-11-10

Publications (1)

Publication Number Publication Date
AR124036A1 true AR124036A1 (es) 2023-02-08

Family

ID=73288427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103113A AR124036A1 (es) 2020-11-10 2021-11-09 Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición

Country Status (10)

Country Link
US (2) US20220168242A1 (enExample)
EP (1) EP4243801A1 (enExample)
JP (1) JP2023548429A (enExample)
KR (1) KR20230106659A (enExample)
CN (1) CN116685314A (enExample)
AR (1) AR124036A1 (enExample)
AU (1) AU2021378472A1 (enExample)
CA (1) CA3198266A1 (enExample)
TW (1) TW202233169A (enExample)
WO (1) WO2022101227A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3268423A1 (en) * 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts thereof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203511A (zh) 2005-06-23 2008-06-18 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
JP6245983B2 (ja) * 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
US9006227B2 (en) 2011-04-19 2015-04-14 Integrative Research Laboratories Sweden Ab Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
EP2858649B1 (en) * 2012-06-11 2019-10-23 Psychogenics Inc. Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
CA2986891C (en) * 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US12275694B2 (en) * 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Also Published As

Publication number Publication date
EP4243801A1 (en) 2023-09-20
CN116685314A (zh) 2023-09-01
US20240148674A1 (en) 2024-05-09
US20220168242A1 (en) 2022-06-02
TW202233169A (zh) 2022-09-01
WO2022101227A1 (en) 2022-05-19
KR20230106659A (ko) 2023-07-13
AU2021378472A1 (en) 2023-06-15
JP2023548429A (ja) 2023-11-16
CA3198266A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
BR112022018173A2 (pt) Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo
ECSP23054131A (es) Cocristal de un inhibidor de cdk
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
AR127050A1 (es) Compuestos espirocíclicos
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
MX2024010104A (es) Compuesto bicíclico condensado que contiene pirrolinona.
DOP2025000090A (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
MX2026001703A (es) Preparacion farmaceutica de un derivado de piperazina, metodo de preparacion de la misma y uso de la misma
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
CL2025001273A1 (es) Compuesto bicíclico fusionado
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.
CO2024015686A2 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer
MX2024009184A (es) Compuesto que contiene grupo hidrazino.
MX2019003585A (es) Derivados de tetrahidropiridina y su uso como agentes antibacterianos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal